{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:27:15Z","timestamp":1774960035234,"version":"3.50.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:p>Despite a European expert consensus statement on the systemic treatment of alopecia areata, the absence of global guidelines and limited information on the long-term safety of JAKi use still poses challenges to clinicians. A cross-sectional survey was conducted to assess the use of JAKi in AA among consultant dermatologists in Ireland.<\/jats:p>","DOI":"10.1093\/skinhd\/vzag001","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T12:24:08Z","timestamp":1767443048000},"page":"180-183","source":"Crossref","is-referenced-by-count":0,"title":["Irish dermatologists\u2019 experience with JAK inhibitors in alopecia areata"],"prefix":"10.1093","volume":"6","author":[{"given":"Cristina","family":"Grechin","sequence":"first","affiliation":[{"name":"Dermatology Department, Beaumont Hospital , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"O\u2019Kane","sequence":"additional","affiliation":[{"name":"Dermatology Department, Beaumont Hospital , Dublin ,","place":["Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026033107432984600_vzag001-B1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: a review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026033107432984600_vzag001-B2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026033107432984600_vzag001-B3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2026033107432984600_vzag001-B4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/jdv.19741","article-title":"A new era for alopecia areata: new treatments and improved knowledge of the condition","volume":"38","author":"Piraccini","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026033107432984600_vzag001-B5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomised clinical trial","volume":"160","author":"King","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026033107432984600_vzag001-B6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2026033107432984600_vzag001-B7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/2\/180\/66937814\/vzag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/2\/180\/66937814\/vzag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:43:32Z","timestamp":1774957412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/2\/180\/8487718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":7,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag001","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,16]]}}}